vs
NEUROCRINE BIOSCIENCES INC（NBIX）与罗致恒富（RHI）财务数据对比。点击上方公司名可切换其他公司
罗致恒富的季度营收约是NEUROCRINE BIOSCIENCES INC的1.6倍（$1.3B vs $805.5M），NEUROCRINE BIOSCIENCES INC同比增速更快（28.3% vs -5.8%），NEUROCRINE BIOSCIENCES INC自由现金流更多（$386.0M vs $170.8M），过去两年NEUROCRINE BIOSCIENCES INC的营收复合增速更高（25.0% vs -6.1%）
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
罗致恒富是1948年成立的国际人力资源咨询机构，总部位于加利福尼亚州门洛帕克和圣拉蒙，是全球规模领先的会计与金融领域人才派遣服务商之一，在全球范围内设有超过345个办公点。
NBIX vs RHI — 直观对比
营收规模更大
RHI
是对方的1.6倍
$805.5M
营收增速更快
NBIX
高出34.1%
-5.8%
自由现金流更多
NBIX
多$215.2M
$170.8M
两年增速更快
NBIX
近两年复合增速
-6.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $805.5M | $1.3B |
| 净利润 | $153.7M | — |
| 毛利率 | 97.8% | 37.6% |
| 营业利润率 | 26.2% | 1.7% |
| 净利率 | 19.1% | — |
| 营收同比 | 28.3% | -5.8% |
| 净利润同比 | 49.1% | — |
| 每股收益（稀释后） | $1.49 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NBIXRHI
| Q4 25 | $805.5M | $1.3B | ||
| Q3 25 | $794.9M | $1.4B | ||
| Q2 25 | $687.5M | $1.4B | ||
| Q1 25 | $572.6M | $1.4B | ||
| Q4 24 | $627.7M | $1.4B | ||
| Q3 24 | $622.1M | $1.5B | ||
| Q2 24 | $590.2M | $1.5B | ||
| Q1 24 | $515.3M | $1.5B |
净利润NBIXRHI
| Q4 25 | $153.7M | — | ||
| Q3 25 | $209.5M | $42.9M | ||
| Q2 25 | $107.5M | $41.0M | ||
| Q1 25 | $7.9M | $17.4M | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $129.8M | $65.5M | ||
| Q2 24 | $65.0M | $68.2M | ||
| Q1 24 | $43.4M | $63.7M |
毛利率NBIXRHI
| Q4 25 | 97.8% | 37.6% | ||
| Q3 25 | 98.2% | 37.2% | ||
| Q2 25 | 98.4% | 37.2% | ||
| Q1 25 | 98.4% | 36.9% | ||
| Q4 24 | 98.5% | 38.8% | ||
| Q3 24 | 98.7% | 39.0% | ||
| Q2 24 | 98.4% | 39.2% | ||
| Q1 24 | 98.5% | 38.1% |
营业利润率NBIXRHI
| Q4 25 | 26.2% | 1.7% | ||
| Q3 25 | 30.1% | 1.0% | ||
| Q2 25 | 21.2% | 0.1% | ||
| Q1 25 | 4.1% | 2.9% | ||
| Q4 24 | 22.6% | 4.7% | ||
| Q3 24 | 29.5% | 4.1% | ||
| Q2 24 | 24.6% | 5.1% | ||
| Q1 24 | 19.3% | 2.8% |
净利率NBIXRHI
| Q4 25 | 19.1% | — | ||
| Q3 25 | 26.4% | 3.2% | ||
| Q2 25 | 15.6% | 3.0% | ||
| Q1 25 | 1.4% | 1.3% | ||
| Q4 24 | 16.4% | — | ||
| Q3 24 | 20.9% | 4.5% | ||
| Q2 24 | 11.0% | 4.6% | ||
| Q1 24 | 8.4% | 4.3% |
每股收益（稀释后）NBIXRHI
| Q4 25 | $1.49 | $0.32 | ||
| Q3 25 | $2.04 | $0.43 | ||
| Q2 25 | $1.06 | $0.41 | ||
| Q1 25 | $0.08 | $0.17 | ||
| Q4 24 | $1.00 | $0.53 | ||
| Q3 24 | $1.24 | $0.64 | ||
| Q2 24 | $0.63 | $0.66 | ||
| Q1 24 | $0.42 | $0.61 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $713.0M | $464.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.3B | $1.3B |
| 总资产 | $4.6B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NBIXRHI
| Q4 25 | $713.0M | $464.4M | ||
| Q3 25 | $340.2M | $365.3M | ||
| Q2 25 | $264.0M | $380.5M | ||
| Q1 25 | $194.1M | $342.5M | ||
| Q4 24 | $233.0M | $537.6M | ||
| Q3 24 | $349.1M | $570.5M | ||
| Q2 24 | $139.7M | $547.4M | ||
| Q1 24 | $396.3M | $540.9M |
股东权益NBIXRHI
| Q4 25 | $3.3B | $1.3B | ||
| Q3 25 | $3.0B | $1.3B | ||
| Q2 25 | $2.7B | $1.3B | ||
| Q1 25 | $2.5B | $1.3B | ||
| Q4 24 | $2.6B | $1.4B | ||
| Q3 24 | $2.7B | $1.5B | ||
| Q2 24 | $2.5B | $1.5B | ||
| Q1 24 | $2.4B | $1.5B |
总资产NBIXRHI
| Q4 25 | $4.6B | $2.9B | ||
| Q3 25 | $4.3B | $2.8B | ||
| Q2 25 | $3.9B | $2.8B | ||
| Q1 25 | $3.7B | $2.7B | ||
| Q4 24 | $3.7B | $2.9B | ||
| Q3 24 | $3.5B | $3.0B | ||
| Q2 24 | $3.3B | $2.9B | ||
| Q1 24 | $3.5B | $2.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $388.4M | $182.5M |
| 自由现金流经营现金流 - 资本支出 | $386.0M | $170.8M |
| 自由现金流率自由现金流/营收 | 47.9% | 13.1% |
| 资本支出强度资本支出/营收 | 0.3% | 0.9% |
| 现金转化率经营现金流/净利润 | 2.53× | — |
| 过去12个月自由现金流最近4个季度 | $743.9M | $266.8M |
8季度趋势，按日历期对齐
经营现金流NBIXRHI
| Q4 25 | $388.4M | $182.5M | ||
| Q3 25 | $227.5M | $77.4M | ||
| Q2 25 | $102.0M | $119.4M | ||
| Q1 25 | $64.8M | $-59.3M | ||
| Q4 24 | $242.5M | $154.8M | ||
| Q3 24 | $158.0M | $129.6M | ||
| Q2 24 | $64.6M | $142.0M | ||
| Q1 24 | $130.3M | $-15.9M |
自由现金流NBIXRHI
| Q4 25 | $386.0M | $170.8M | ||
| Q3 25 | $214.3M | $63.6M | ||
| Q2 25 | $89.5M | $104.2M | ||
| Q1 25 | $54.1M | $-71.7M | ||
| Q4 24 | $235.2M | $140.5M | ||
| Q3 24 | $149.9M | $111.8M | ||
| Q2 24 | $53.0M | $129.6M | ||
| Q1 24 | $119.1M | $-27.7M |
自由现金流率NBIXRHI
| Q4 25 | 47.9% | 13.1% | ||
| Q3 25 | 27.0% | 4.7% | ||
| Q2 25 | 13.0% | 7.6% | ||
| Q1 25 | 9.4% | -5.3% | ||
| Q4 24 | 37.5% | 10.2% | ||
| Q3 24 | 24.1% | 7.6% | ||
| Q2 24 | 9.0% | 8.8% | ||
| Q1 24 | 23.1% | -1.9% |
资本支出强度NBIXRHI
| Q4 25 | 0.3% | 0.9% | ||
| Q3 25 | 1.7% | 1.0% | ||
| Q2 25 | 1.8% | 1.1% | ||
| Q1 25 | 1.9% | 0.9% | ||
| Q4 24 | 1.2% | 1.0% | ||
| Q3 24 | 1.3% | 1.2% | ||
| Q2 24 | 2.0% | 0.8% | ||
| Q1 24 | 2.2% | 0.8% |
现金转化率NBIXRHI
| Q4 25 | 2.53× | — | ||
| Q3 25 | 1.09× | 1.80× | ||
| Q2 25 | 0.95× | 2.91× | ||
| Q1 25 | 8.20× | -3.42× | ||
| Q4 24 | 2.35× | — | ||
| Q3 24 | 1.22× | 1.98× | ||
| Q2 24 | 0.99× | 2.08× | ||
| Q1 24 | 3.00× | -0.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
RHI
| Finance And Accounting | $535.2M | 41% |
| Protiviti | $479.0M | 37% |
| Technology | $156.4M | 12% |
| Permanent Placement Talent Solutions | $102.6M | 8% |
| Other | $29.2M | 2% |
